Idarucizumab: First Global Approval-Reference-Cited by-同舟云学术

Idarucizumab: First Global Approval

Published:2015-11-17 Issue:18 Volume:75 Page:2155-2161
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Burness Celeste B.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-015-0508-5.pdf

Reference28 articles.

1. Boehringer Ingelheim. Pradaxa® (dabigatran etexilate mesylate) capsules for oral use: US prescribing infomation. 2015. http://www.boehringer-ingelheim.com/ . Accessed 19 Oct 2015.

2. European Medicines Agency. Pradaxa 110 mg hard capsules: summary of product characteristics. 2015. http://www.ema.europa.eu/ . Accessed 19 Oct 2015.

3. Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombol. 2015;39(3):395–402.

4. Costin J, Ansell J, Laulicht B, et al. Reversal agents in development for the new oral anticoagulants. Postgrad Med. 2014;126(7):19–24.

5. Boehringer Ingelheim. Praxbind® (idarucizumab) injection, for intravenous use: US prescribing information. 2015. http://us.boehringer-ingelheim.com . Accessed 2015.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein engineering of antibody fragments for pharmaceutical production;Applied Physics Reviews;2023-09-01

2. When and How to Use Reversal Agents for Direct Oral Anticoagulants?;Current Cardiology Reports;2023-03-28

3. A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database;Pharmaceuticals;2023-03-17

4. Bioengineering of Antibody Fragments: Challenges and Opportunities;Bioengineering;2023-01-17

5. Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021;Biomedicines;2022-09-19